Sergio Teruya
Overview
Explore the profile of Sergio Teruya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chan N, Einstein A, Teruya S, Rodriguez C, Helmke S, Cuomo M, et al.
Am J Cardiol
. 2024 Nov;
237:60-64.
PMID: 39581521
Transthyretin cardiac amyloidosis (ATTR-CA) is disproportionately diagnosed in older men. However, studies suggest that the true prevalence of ATTR-CA in women may be greater than previously reported. The Screening for...
2.
Urina-Jassir M, Teruya S, Blaner W, Brun P, Prokaeva T, Tsai F, et al.
JACC Heart Fail
. 2024 Aug;
12(12):2113-2115.
PMID: 39115519
No abstract available.
3.
Wardhere A, Bampatsias D, Mirabal-Santos A, Weinsaft A, Guadalupe S, De Los Santos J, et al.
Am J Cardiol
. 2024 Jul;
228:70-77.
PMID: 39067579
Anemia is prevalent in transthyretin amyloid cardiomyopathy (ATTR-CM), but its prognostic significance remains uncertain because of conflicting data mainly in patients not receiving disease-modifying therapy. Additionally, the effect of anemia...
4.
Lang F, Teruya S, Cuomo M, Santos A, Radhakrishnan J, Lentzsch S, et al.
J Card Fail
. 2024 Jul;
30(12):1641-1646.
PMID: 38997000
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated benefit in patients with heart failure, but minimal data exist concerning the use of these medications in amyloid light-chain cardiomyopathy (AL-CM). We performed...
5.
Thel M, Cochran J, Teruya S, Hayashi O, Xie C, Srinivasan A, et al.
Circ Heart Fail
. 2024 Jun;
17(8):e011681.
PMID: 38853760
No abstract available.
6.
Wardhere A, Bampatsias D, Cohn E, Fine D, de Freitas C, Gallegos C, et al.
J Card Fail
. 2024 May;
30(11):1507-1511.
PMID: 38740174
Background: The Screening for Cardiac Amyloidosis with Nuclear Imaging in Minority Populations study seeks to determine the prevalence of transthyretin cardiac amyloidosis (ATTR-CA) among older Black or Caribbean Hispanic individuals...
7.
Lang F, Teruya S, Weinsaft A, Cuomo M, Santos A, Nalbandian A, et al.
Eur J Heart Fail
. 2024 Mar;
26(4):938-947.
PMID: 38488292
Aims: Despite their potential, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have not been well-studied in transthyretin amyloid cardiomyopathy (ATTR-CM) as randomized trials have excluded patients with this morbid disease. We performed...
8.
Chan N, Teruya S, Mirabal A, Weinsaft A, De Los Santos J, Guadalupe S, et al.
J Card Fail
. 2024 Mar;
30(9):1100-1107.
PMID: 38458484
Background: Transthyretin cardiac amyloidosis (ATTR-CA) is increasingly recognized. Clinical outcomes have evolved over time amid changes in the diagnostic pathway and advances in therapeutics. We sought to evaluate clinical outcomes...
9.
Petros F, Santos A, Adeniyi A, Teruya S, De Los Santos J, Maurer M, et al.
Amyloid
. 2024 Mar;
31(2):116-123.
PMID: 38433466
Background: Transthyretin cardiac amyloidosis (ATTR cardiac amyloidosis) is caused by variant (ATTRv) or wild type (ATTRwt) transthyretin. While gait abnormalities have been studied in younger patients with ATTRv amyloidosis, research...
10.
Madhani A, Sabogal N, Massillon D, Paul L, Rodriguez C, Fine D, et al.
J Am Heart Assoc
. 2023 Jul;
12(15):e028973.
PMID: 37486082
Background Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure (HF) among patients ≥60 years of age. Although the V122I (valine to isoleucine substitution at position 122 of...